Klin Farmakol Farm. 2016;30(3):15-17 | DOI: 10.36290/far.2016.023

Dabigatran - clinical evidence for treatment in patients with thromboembolism

Tomáš Kvasnička
Trombotické centrum, ÚLBLD, VFN a 1. LF UK Praha

Venous thromboembolism (VTE) is due to its incidence, morbidity and mortality an important global socioeconomical problem. Antithrombotic prevention and treatment are one of the most common areas in moderne medicine. TEN is still the frequent causes of mortality and morbidity. We are currently used in this field heparins, pentasaccharide and warfarin. Warfarin despites undoubted effect, especially for its interindividual variability, the risk of drug and food interactions and a narrow therapeutic window. The development of new, effective oral anticoagulants (NOAC) focused mainly on direct thrombin inhibitors and direct factor Xa inhibitor. From the first group is used in several indications in the Czech Republic dabigatran etexilate (Pradaxa).

Keywords: Pradaxa, dabigatran etexilate, thromboembolic disease, atrial fibrillation

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvasnička T. Dabigatran - clinical evidence for treatment in patients with thromboembolism. Klin Farmakol Farm. 2016;30(3):15-17. doi: 10.36290/far.2016.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kvasnička J, Kvasnička J. jr. Trombofilie a trombotické stavy v klinické praxi. Praha, nakl. Grada Publ., 2003: s. 300.
    2. Ahrens I, et al. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60. Go to original source... Go to PubMed...
    3. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127. Go to original source... Go to PubMed...
    4. Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    5. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303. Go to original source... Go to PubMed...
    6. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharma-cokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59. Go to original source... Go to PubMed...
    7. Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet 2010; 49: 259-268. Go to original source... Go to PubMed...
    8. Eliquis. Souhrn údajů o přípravku. www. sukl.cz.
    9. Čihák R, Haman L, Táborský M. Praktická doporučení European Heart Rhythm Association pro použití nových perorálních antikoagulancií u pacientů s nevalvulární fibrilací síní. Cor Vasa 2014; 56: e42-e56. Go to original source...
    10. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562. Go to original source... Go to PubMed...
    11. Praxbind. Souhrn údajů o přípravku. www. sukl.cz.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.